Evidence map›Paper›PMID 41930182›Full record

ArticleOncology research2026

PSMD2-Mediated MAPK Signaling Promotes Bladder Cancer Development and Immune Microenvironment Remodeling.

Shuwen Sun, Jingcheng Zhang, Zongtai Zheng, Yajuan Hao, Tianyuan Xu, Ji Liu, Liang Sun, Aimin Wang, Yadong Guo, Shiyu Mao and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shuwen SunDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, China.
Jingcheng ZhangDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, China.
Zongtai ZhengDepartment of Urology, The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, 510317, China.
Yajuan HaoDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, China.
Tianyuan XuDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, China.
Ji LiuDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, China.
Liang SunDepartment of Urology, Bengbu First People's Hospital, Bengbu, 233000, China.
Aimin WangDepartment of Urology, Bengbu First People's Hospital, Bengbu, 233000, China.
Yadong GuoDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, China.
Shiyu MaoDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, China.
Xu ZhangBio-X Institutes (Key Laboratory for the Genetics of Development and Neuropsychiatric Disorders), Shanghai Jiao Tong University, Shanghai, 200240, China.
Yunfei XuDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, China.
Yifan ChenDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, China.
Yang YanDepartment of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Bladder cancer (BCa) progression is closely linked to the immune microenvironment. However, the key molecules that regulate this microenvironment and their specific mechanisms remain poorly understood. This study aims to identify a key molecule and elucidate its mechanisms, providing a theoretical basis for identifying novel therapeutic targets. Methods: Immune microenvironment-related genes in BCa were identified using The Cancer Genome Atlas and Shanghai Tenth People's Hospital datasets. Proteasome 26S subunit non-ATPase 2 (PSMD2) expression was validated via quantitative polymerase chain reaction (qPCR), Western blot (WB) analysis, and immunofluorescence (IF). Results: PSMD2 was identified as a critical factor in BCa, with high expression correlating with poor prognosis and tumor progression. Mechanistically, PSMD2 enhances malignancy by promoting mitogen-activated protein kinase kinase (MEK) and extracellular signal-regulated kinase (ERK) phosphorylation within the mitogen-activated protein kinase (MAPK) signaling pathway. Combined bioinformatics and experimental analyses reveal that PSMD2 downregulates chemokine (C-X-C motif) ligand 14 (CXCL14) expression and secretion via the MAPK pathway, thereby remodeling the immune microenvironment and driving tumor progression. Pathomics analysis further supports the potential of PSMD2 expression as a predictive marker in BCa tissues. Conclusion: PSMD2 is overexpressed in BCa and significantly correlates with poor prognosis and tumor progression. It promotes malignant development and immune microenvironment remodeling through the MAPK pathway. Pathological analysis can predict PSMD2 expression, offering valuable insights into immunotherapy responses and survival outcomes.

Indexed as

MAP Kinase Signaling SystemProteasome Endopeptidase ComplexTumor MicroenvironmentUrinary Bladder NeoplasmsAnimalsCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansMicePrognosisProteasome Endopeptidase ComplexBladder cancer (BCa)C-X-C motif chemokine ligand 14 (CXCL14)immune infiltrationproteasome 26S subunit non-ATPase 2 (PSMD2)

Identifiers

PMID41930182
PMCPMC13040311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.